Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PainChek Ltd ( (AU:PCK) ) has provided an announcement.
PainChek Limited announced a change in the director’s interest, with Philip Daffas converting 2,360,718 performance rights into fully paid ordinary shares and allowing 4,804,177 performance rights to lapse. This change reflects a strategic adjustment in the director’s holdings, potentially impacting the company’s stock dynamics and signaling confidence in the company’s future prospects.
More about PainChek Ltd
PainChek Limited operates in the healthcare technology industry, offering innovative pain assessment solutions. The company’s primary product is an AI-powered pain assessment tool designed to improve pain management, particularly for individuals unable to communicate their pain effectively.
Average Trading Volume: 4,932,528
Technical Sentiment Signal: Buy
Current Market Cap: A$102.3M
Find detailed analytics on PCK stock on TipRanks’ Stock Analysis page.